Comparative Pharmacology
Head-to-head clinical analysis: JUNEL FE 1 20 versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL FE 1 20 versus TRI MILI.
JUNEL FE 1/20 vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive